Comparison of fecal pyruvate kinase isoform M2 and calprotectin in assessment of pediatric inflammatory bowel disease severity and activity.

  • Elzbieta Czub Child & Mother Specialist Hospital in Poznan, Poznań, Poland.;
  • Jan K Nowak Poznan University of Medical Sciences, Department of Pediatric Gastroenterology & Metabolic Diseases, Poznań, Poland.;
  • Anna Szaflarska-Poplawska Nicolaus Copernicus University, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Department of Pediatric Endoscopy and Gastrointestinal Function Testing, Bydgoszcz, Poland.;
  • Urszula Grzybowska-Chlebowczyk Medical University of Silesia, Department of Paediatrics, Katowice, Poland.;
  • Piotr Landowski Medical University of Gdansk, Department of Pediatrics, Pediatric Gastroenterology, Hepatology and Nutrition, Gdańsk, Poland.;
  • Jerzy Moczko Poznan University of Medical Sciences, Department of Informatics and Statistics, Poznań, Poland.;
  • Daria Adamczak Poznan University of Medical Sciences, Poznań, Poland.;
  • Przemyslaw Mankowski Poznan University of Medical Sciences, Department of Paediatric Surgery, Traumatology and Urology, Poznań, Poland.;
  • Tomasz Banasiewicz Poznan University of Medical Sciences, Department of General, Gastroenterological and Endocrinological Surgery, Poznań, Poland.;
  • Andrzej Plawski Institute of Human Genetics, Polish Academy of Sciences, Poznań, Poland.;
  • Jaroslaw Walkowiak Poznan University of Medical Sciences, Department of Pediatric Gastroenterology & Metabolic Diseases, Poznań, Poland.;
DOI: https://doi.org/10.18388/abp.2014_1929

Abstract

Accurate assessment of inflammatory bowel disease (IBD) activity is the cornerstone of effective therapy. Fecal M2 isoform of pyruvate kinase (M2-PK) and fecal calprotectin (FC) are noninvasive markers of mucosal inflammation in IBD. The aim of this study was to compare performance of M2-PK and FC in assessment of pediatric ulcerative colitis (UC) and Crohn's disease (CD) severity and activity. 121 patients with IBD, including 75 with UC and 46 with CD were recruited. Control group consisted of 35 healthy children (HS). Patients were assigned to groups depending on disease severity and activity. M2-PK and calprotectin concentration were determined in stool samples using ELISA. Areas under receiver operating characteristic curves (AUC) for FC and M2-PK with cut-off level at which M2-PK specificity was matching FC specificity were calculated and compared. Performance of M2-PK at identifying patients with IBD, UC and CD among HS was inferior to FC. The differences in AUC were respectively: -0.10 (95% confidence interval [CI] [-0.13-(-0.06)], p<0.0001), -0.14 (95% CI [-0.19-(-0.09)], p<0.0001) and -0.03 (95% CI [-0.05-(-0.001)], p<0.02). M2-PK was inferior to FC in discriminating patients with mild UC from those with HS (AUC difference -0.23, 95% CI [-0.31-(-0.15)], p<0.0001). FC reflects pediatric IBD severity and activity better than M2-PK. This difference is particularly pronounced when identifying patients with mild UC and UC in remission.
Published
2014-03-20
Issue
Vol. 61 No. 1 (2014)
Section
Articles

Acta Biochimica Polonica is an OpenAccess quarterly and publishes four issues a year. All contents are distributed under the Creative Commons Attribution-ShareAlike 4.0 International (CC BY 4.0) license. Everybody may use the content following terms: Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

Copyright for all published papers © stays with the authors.

Copyright for the journal: © Polish Biochemical Society.